NASDAQ: FBIO - Fortress Biotech, Inc.

Rentabilidade por seis meses: +41.32%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Fortress Biotech, Inc.


Sobre a empresa Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.

mais detalhes
It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

IPO date 2011-11-17
ISIN US34960Q1094
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.fortressbiotech.com
Цена ао 1.93
Alteração de preço por dia: +14.56% (2.06)
Alteração de preço por semana: +37.21% (1.72)
Alteração de preço por mês: +28.96% (1.83)
Alteração de preço em 3 meses: +58.39% (1.49)
Mudança de preço em seis meses: +41.32% (1.67)
Mudança de preço por ano: -21.59% (3.01)
Mudança de preço em 3 anos: +804.21% (0.261)
Mudança de preço em 5 anos: +1 104.08% (0.196)
Mudança de preço em 10 anos: 0% (2.36)
Mudança de preço desde o início do ano: +36.42% (1.73)

Subestimação

Nome Significado Nota
P/S 0.2639 10
P/BV 14.05 1
P/E 0 0
EV/EBITDA -0.2285 0
Total: 5.13

Eficiência

Nome Significado Nota
ROA, % -36.2 0
ROE, % -268.97 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.536 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 130.91 10
Rentabilidade Ebitda, % 29 4
Rentabilidade EPS, % 689.52 10
Total: 6.4

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
iShares Micro-Cap ETF 0.00549 17.09 1.54048



Supervisor Cargo Pagamento Ano de nascimento
Dr. Lindsay Allan Rosenwald Executive Chairman, President & CEO 212.66k 1955 (70 anos)
Mr. Michael S. Weiss Esq. Executive Vice Chairman of Strategic Development & Director 182.66k 1966 (59 anos)
Mr. David Jin CFO & Head of Corporate Development 407.33k 1990 (35 anos)
Dr. George C. Avgerinos Senior Vice President of Biologics Operations 386.49k 1954 (71 ano)
Mr. Samuel Berry General Counsel & Corporate Secretary N/A

Endereço: United States, Bay Harbor Islands. FL, 1111 Kane Concourse - abrir no Google Maps, abrir mapas Yandex
Site: https://www.fortressbiotech.com